Last reviewed · How we verify

Klaricid based triple therapy

National Taiwan University Hospital · FDA-approved active Small molecule ✓ Verified Jun 2026 Quality 2/100

Klaricid based triple therapy is a Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved.

Klaricid, a small molecule, is used in triple therapy for the treatment of Helicobacter Pylori Infection. The triple therapy is one of the interventions studied for treating H. Pylori Infection, along with sequential and hybrid therapies, in real-world settings.

At a glance

Generic nameKlaricid based triple therapy
SponsorNational Taiwan University Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Klaricid based triple therapy

What is Klaricid based triple therapy?

Klaricid based triple therapy is a Small molecule drug developed by National Taiwan University Hospital.

Who makes Klaricid based triple therapy?

Klaricid based triple therapy is developed and marketed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).

What development phase is Klaricid based triple therapy in?

Klaricid based triple therapy is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing